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1. Introduction 
Parkinson’s disease (PD) is one of the most common chronic neurodegenerative disorders. It 
is characterized by a variety of motor (bradykinesia, rigidity, tremor, and postural 
instability) and nonmotor (autonomic disturbances and psychosis) symptoms. Although it 
can be diagnosed accurately, no therapeutic strategies can cure or completely block the 
progression of PD. Pathologically, PD is characterized by the severe loss of dopaminergic 
(DAergic) neurons in the pars-compacta nigra and the presence of proteinaceous -
synuclein inclusions, called Lewy bodies (LBs), which are present in neurons of the central 
nervous system (specific cortical regions, brain stem, and spinal cord), peripheral autonomic 
nervous system, enteric nervous system (ENS), and cutaneous nerves (Braak et al., 2006; 
Ikemura et al., 2008; Lebouvier et al., 2009). Similar to other neurodegenerative diseases, 
such as Alzheimer’s disease, age is the major risk factor for PD although 10% of the people 
with the disease are younger than 45.  
Although PD is regarded as a sporadic disorder, remarkably few environmental causes or 
triggers have been identified (Dick et al., 2007; Tanner, 2003; Taylor et al., 2005). Pesticides 
and herbicides are the most likely candidates for environmental agents associated with the 
pathogenesis of PD. On the other hand, PD characteristics are seen in a number of familial 
motor disorders caused by different genetic factors. Animal models of neurodegenerative 
diseases, including PD, have in general been quite instructive in understanding their 
pathogenesis. Ideally, animal models of PD, whether induced by environmental risk factors 
(neurotoxins) or genetic manipulations, should faithfully reproduce the clinical 
manifestations (behavioral abnormalities), pathological features, and molecular 
dysfunctions characterizing the disease. Unfortunately, animal models rarely mimic the 
etiology, progression, and pathology of PD completely, and in most cases, only partial 
insight can be gained from these studies. Despite these difficulties, animal models are 
considered to be very helpful in the development of therapies to treat PD. In this paper, we 
discuss recently developed neurotoxin-induced and genetic model animals of PD.  
Over the years, many chemical compounds and toxin have been identified causative agents 
of PD. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a representative strong 
neurotoxin that has been recognized from several young drug addicts developed severe 
parkinsonism. The addicts illegally achieved street preparations of drugs and products were 
contaminated with MPTP. In addition, epidemiologically, environmental neurotoxins such 
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as agricultural chemicals (pesticides, herbicides, and fungicides) are promising candidates 
for causative factors of PD. Rotenone and paraquat could promote and accelerate the 
development of PD. Oxidative stress and mitochondrial dysfunction induced by these toxins 
could contribute to the progression of PD. While most cases of PD are sporadic, specific 
mutations in genes that cause familial forms of PD have led to provide new insights into its 
pathogenesis. Analysis of these gene products may provide vital clues to our understanding 
of the molecular pathogenesis of dopaminergic neuronal death in PD. 
Over 10 causative genes for autosomal-dominant (-synuclein, Ubiqitin carboxy-terminal 
hydrolase L1 (UCHL1), and Leucine-rich repeat kinase 2 (LRRK2)) or autosomal-recessive 
(parkin, phosphatase and tensin homolog deleted on chromosome ten (PTEN)-induced putative kinase 
1 (PINK1), and DJ-1 inheritance PD have been identified and classified for PARK loci. 
Studying animal models are important tools in experimental medical science for 
understanding the pathogenesis and therapeutic intervention strategies of human diseases, 
including neurodegenerative diseases such as PD. However, it is quite difficult to 
completely reproduce symptomatic and pathological features of human disorders. Since 
many human diseases including PD do not arise spontaneously in animals, in particular, 
characteristic functional changes have to be mimicked by neurotoxic agents. Nevertheless, 
recent studies have indicated excellent neurotoxin-induced animal models of PD. In 
addition, many genetic animal models of familial PD have been generated and recognized 
valuable tools for investigating and understanding pathophysiology of familial and even 
sporadic PD. Apart from the obvious preference for vertebrate (rodents and primates) 
models to investigate PD, an increasing number of studies have also shown a number of 
advantages and the utility of invertebrate (flies and nematodes) models. The central nervous 
system of invertebrate animal has a rather small number of neuron and glia as compared to 
vertebrates, however, essential functional features such as neurotransmitter system of 
vertebrates and invertebrates are conserved. This chapter focuses on animal models of both 
toxin-induced and genetically determined PD that have provided significant insight for 
understanding this disease. We also discuss the validity, benefits, and limitations of 
representative models.  
2. Neurotoxin-induced animal models of PD  
PD is currently viewed as a multifactorial disease. Environmental exposures, particularly to 
pesticides, are thought to be involved in the pathogenesis of sporadic PD. Specifically, the 
herbicide Paraquat (PQ) and the fungicide Maneb (manganese ethylene-bis-
dithiocarbamate) have been associated with the incidence of PD (Ascherio et al., 2006; Ferraz 
et al., 1988). However, a causal role for pesticides in the etiology of PD has yet to be 
definitively established. In animal models, PD-like disorders induced by neurotoxins or 
other chemical compounds have led to a better understanding of the pathophysiology of PD 
(Table 1).  
2.1 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) 
In 1979 and 1983, MPTP was initially identified as a strong neurotoxin when heroin addicts 
accidentally self-administered MPTP and developed an acute form of parkinsonism that 
was indistinguishable from idiopathic PD (Davis et al., 1979; Langston et al., 1999). A 
detailed neuropathological study of MPTP-induced parkinsonism in humans showed severe 
neuronal degeneration in the substantia nigra and the absence of LBs (Langston, et al., 1999). 
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Neurotoxin Behavioral and Pathological Features Molecular Mechanisms 
MPTP 
1) Parkinsonism (akinesia, rigidity, and tremor) 
with acute onset 
2) Relatively less potent in rodents 
3) Good response to L-DOPA and DA-agonists 
4) Loss of TH-neurons (-fibers) and DA-content 
in nigrostriatal region 
5) Loss of TH-neurons (-fibers) in ENS 
6) -Synuclein-positive inclusions 
7) No typical LBs 
1) Easily crosses the BBB 
2) Converted to MPP+ in glial cells 
3) Transferred into mitochondria 
by transporters 
4) Inhibits electron transport 
chain complex I 
5) Upregulation of iNOS, 
NADPH-oxidase, and ROS 
6) Microglial activation 
6-OHDA 
1) Intracerebral administration  
2) Quantifiable locomotor abnormalities 
(rotation, akinsesia)  
3) Good response to L-DOPA and DA-agonists 
4) Loss of TH-neurons (-fibers) and DA-content 
in nigrostriatal region 
5) No typical LBs 
1) Transferred into mitochondria 
by transporters 
2) Inhibits electron transport 
chain complex I 
3) Microglial activation 
Rotenone 
1) Parkinsonism (bradykinesia, fixed posture, 
and rigidity) 
2) Good response to L-DOPA and DA-agonists 
3) Loss of TH-neurons (-fibers) and DA-content 
in nigrostriatal region 
4) -Synuclein-positive inclusions, resemblance 
to true LBs 
5) Loss of myenteric neurons 
1) Easily crosses the BBB 
2) Inhibits electron transport 
chain complex I 
3) Upregulation of NADPH-
oxidase 
4) Microglial activation 
Paraquat 
(+ Maneb) 
1) Parkinsonism similar to that of induced by 
MPTP 
2) Loss of DA-content in nigrostriatal region 
3) -Synuclein-positive inclusions with long 
exposure 
1) Crosses the BBB by neutral 
amino acid transporter 
2) Inhibits electron transport 
chain complex I 
3) Reduction of nAchR-mediated 
DA release 
4) Inhibits complex III (Maneb) 
Abbreviations: MPTP, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 6-OHDA, 6-hydroxy-dopamine; 
Maneb, manganese ethylene-bis-dithiocarbamate; L-DOPA, L-3,4-dihydroxy-L-phenylalanine; TH, 
tyrosine hydroxylase; DA, dopamine; ENS, enteric nervous system; LB, Lewy body; BBB, blood-brain 
barrier; MPP+, 1-methyl-4-phenylpyridinium; iNOS, inducible nitric oxide synthase; ROS, reactive 
oxygen species; NADPH, nicotinamide adenine dinucleotide phosphate; nAchR, nicotinic acetylcholine 
receptor 
Table 1. Representative neurotoxin-induced mammalian models of PD 
The lack of LBs may have reflected the age of the patient and the duration of exposure to 
MPTP. The tragic results of MPTP poisoning in the heroin addicts led to the development of 
MPTP-induced rodent and nonhuman primate animal models of PD, which have proved 
extremely valuable (Chiueh et al., 1984; Kopin & Markey, 1988; Langston et al., 1984; 
Langston & Irwin, 1986; Markey et al., 1984). The MPTP-exposed primates show good 
response to therapy with L-3,4-dihydroxy-L-phenylalanine (L-DOPA) and dopamine (DA) 
receptor agonists (Kopin & Markey, 1988; Langston & Irwin, 1986). However, rats are 
relatively insensitive to MPTP neurotoxicity compared with primates. Rats given MPTP at 
doses comparable to those used in mice do not show remarkable neurodegeneration 
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(Giovanni et al., 1994; Giovanni et al., 1994). Only high doses of MPTP cause DAergic 
neurodegeneration in rats, indicating that complete blockade of the DA receptors is required 
for them to display signs of parkinsonism. Mice, like rats, are also less sensitive to MPTP 
than primates (Przedborski et al., 2001; Schmidt & Ferger, 2001). This model also shows 
pathological changes in the ENS, as observed in PD. In PD, gastrointestinal (GI) dysfunction 
was hypothesized to depend on neuronal degeneration in the ENS that is similar to that 
seen in the CNS. Recent studies show that the administration of MPTP results in decreased 
tyrosine hydroxylase- (TH-) positive enteric neurons in mice, indicating that the MPTP 
model mice should be suitable for understanding the extranigral pathophysiology of PD 
(Anderson et al., 2007; Natale et al., 2010). 
2.2 6-Hydroxy-Dopamine (6-OHDA) 
Like MPTP, 6-OHDA is a neurotoxin that has been successfully used in induction animal 
models of PD. 6-OHDA’s strong neurotoxic effects were described by Ungerstedt in 1971, in 
a study presenting the first example of using a chemical agent to produce an animal model 
of PD (Ungerstedt, 1971). Since 6-OHDA cannot cross the blood-brain barrier (BBB), 
systemic administration fails to induce parkinsonism. This induction model requires 6-
OHDA to be injected into the substantia nigra, medial forebrain bundle, and striatum (Perez 
& Palmiter, 2005; Przedborski et al., 1995). The effects resemble those in the acute MPTP 
model, causing neuronal death over a brief time course (12 hours to 2-3 days). Interestingly, 
the intrastriatal injection of 6-OHDA causes progressive retrograde neuronal degeneration 
in the substantia nigra and ventral tegmental complex (ST-VTA) (Berger et al., 1991; 
Przedborski, et al., 1995; Sauer & Oertel, 1994). As in PD, DAergic neurons are killed, and 
the non-DAergic neurons are preserved. However LBs do not form. Typically, 6-OHDA is 
used as a hemiparkinson model, in which its unilateral injection into the substantia nigra 
causes asymmetric motor behavior (turning, rotation) when apomorphine, a DAergic 
receptor agonist, or amphetamine, a dopamine releasing agent, is given systemically. In this 
model, the quantifiable motor behavior is a major advantage for screening pharmacological 
screening agents for their effects on the DAergic system and for testing cell replacement 
therapies (Beal, 2001; Deumens et al., 2002; Hirsch et al., 2003). 
2.3 Rotenone 
Rotenone is a naturally occurring complex ketone pesticide derived from the roots of 
Lonchocarpus species. It can rapidly cross cellular membranes without the aid of transporters, 
including the BBB. Rotenone is a strong inhibitor of complex I, which is located at the 
innermitochondrial membrane and protrudes into the matrix. In 2000, Betarbet et al. 
demonstrated in rats that chronic systemic exposure to rotenone causes many features of PD, 
including nigrostriatal DAergic degeneration (Betarbet et al., 2000). Importantly, pathological 
features match those seen in typical PD. For example, many of the degenerating neurons have 
intracellular inclusions that are morphologically similar to LBs. These inclusions also show 
immunoreactivity for synuclein and ubiquitin, like true LBs (Betarbet, et al., 2000; Sherer et 
al., 2003). The rotenone-administered model animals also reproduce all the behavioral and 
pathological features seen in the typical form of human PD. However, rotenone-injected rats 
without nigrostriatal DAergic neuronal loss demonstrate the same abnormal motor behaviors 
as those with such pathological features (Lapointe et al., 2004; Sherer, et al., 2003). This finding 
suggested that the abnormal behaviors of PD could depend, at least partly, on the damage to 
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non-DAergic neurons in the nigrostriatal area. Furthermore, rotenone exposure also causes the 
loss of myenteric neurons in the rat (Drolet et al., 2009).  
2.4 Paraquat and maneb 
Because of its close structural similarity to 1-methyl-4-phenylpyridinium (MPP+, the active 
metabolite form of MPTP), an herbicide, 1,1’-dimethyl-4,4’-bipyridinium, named paraquat 
has been suggested as a risk factor for PD (Di Monte et al., 1986). The systemic 
administration of paraquat to adult mice results in a significant decrease in substantia nigra 
DAergic neurons, a decline in striatal dopamine nerve terminal density, and a 
neurobehavioral syndrome characterized by reduced ambulatory activity (Brooks et al., 
1999). These data support the idea that paraquat crosses the BBB to cause destruction of the 
dopamine neurons in the substantia nigra, like MPP+ (Brooks, et al., 1999). The prolonged 
exposure to paraquat leads to a remarkable accumulation of synuclein-like aggregates in 
neurons of the substantia nigra pars compacta in mice (Manning-Bog et al., 2002). Chronic 
exposure to paraquat also reduces the expression of the nicotinic acetylcholine receptor 
(nAChR) subunit 3/62∗ (the asterisk indicates the possible presence of additional 
subunits). Normally, the activation of both nAChR subtypes stimulates DA release in the 
striatum (Khwaja et al., 2007; McCallum et al., 2005; Wonnacott et al., 2000). The injection of 
paraquat selectively reduces the 3/62∗-mediated DA release from the striatum in 
primates (O'Leary et al., 2008). Maneb is an organomanganese fungicide that is broadly used 
in agriculture and is a putative causative agent for PD. Surprisingly, Thiruchelvam et al. 
found that the neurotoxic effects of maneb or paraquat on the nigrostriatal DA system in 
mice are synergistically potentiated in combination (Thiruchelvam et al., 2000). Their report 
argued that this finding has important implications for the human risk of PD, because the 
marked geographical overlap in the estimated annual agricultural applications of paraquat 
and maneb means that people living in these areas may be exposed to the synergistic 
neurotoxicity of these two agents (Thiruchelvam, et al., 2000; Thiruchelvam et al., 2000).  
3. Pathophysiological mechanisms of DAergic neurotoxins  
All the representative neurotoxin-induced PD models described above show defective 
mitochondrial function, manifested by the inhibition of mitochondrial complex I or III. 
MPTP is a highly lipophilic agent. After its systemic administration, MPTP rapidly crosses 
the BBB. Once in the brain, MPTP is converted to 1-methyl-4-phenyl-2,3- dihydropyridium 
(MPDP+) in glial cells (astrocytes) and serotonin neurons by monoamine oxidase B (MAO-
B) and then spontaneously oxidizes to MPP+ (Nicklas et al., 1985; Przedborski & Vila, 2003). 
Thereafter, MPP+ is released into the extracellular space. Unlike MPTP, MPP+ is a polar 
molecule that cannot freely enter DAergic neurons. Thus, a plasma membrane transport 
system is required. MPP+ has a high affinity for dopamine transporter (DAT) as well as for 
norepinephrine and serotonin transporters (Bezard et al., 1999; Mayer et al., 1986). Once 
inside DAergic neurons, MPP+ can accumulate in mitochondria and impair mitochondrial 
respiration by inhibiting complex I in the electron transport chain (Nicklas, et al., 1985; 
Ramsay & Singer, 1986), which induces the generation of reactive oxygen species (ROS). 
MPP+ can also bind to vesicular monoamine transporters (VMATs), which help move 
selected materials into synaptic vesicles containing DA (Del Zompo et al., 1993). MPP+ can 
also remain in the cytoplasm and interact with cytosolic enzymes (Klaidman et al., 1993).  
www.intechopen.com
 
Mechanisms in Parkinson’s Disease – Models and Treatments 328 
Inducible nitric oxide synthase (iNOS) is also involved in the pathogenesis of MPP+-
induced parkinsonism in animal models. Increased iNOS has also been found in the 
substantia nigra of autopsied PD patients, indicating that nitric oxide (NO) overproduction 
is a feature of the human disease (Huerta et al., 2007; Hunot et al., 1996). Excess NO could 
contribute to the formation of free radicals, which could damage DAergic neurons, leading 
to the development of PD symptoms. Mice null for iNOS show a resistance to neuronal 
damage by MPTP, and iNOS inhibitors protect against the degeneration of DAergic neurons 
in MPTP-treated mice (Dehmer et al., 2000; Liberatore et al., 1999). Furthermore, microglial 
cells can be activated by the formation of free radicals and iNOS-mediated damage, and 
thereby exacerbate the toxicity of MPTP (Barcia et al., 2004; Breidert et al., 2002; Wu et al., 
2002). Finally, MPTP can also upregulate nicotinamide adenine dinucleotide phosphate 
(NADPH)-oxidase in the substantia nigra of mice (Wu, et al., 2002), which is significant 
because NADPH-oxidase appears to be ubiquitously expressed in all brain regions and 
metabolizes molecular oxygen, generating superoxide as a product. In fact, MPTP toxicity is 
diminished in mice lacking functional NADPH-oxidase, indicating a pivotal role for 
superoxide ions in the neurotoxicity induced by MPTP (Wu, et al., 2002).  
The toxicity of 6-OHDA also involves mechanisms of oxidative stress. 6-OHDA can be taken 
up by DAergic neurons through DAT (Bove et al., 2005; Schober, 2004). Once transported 
into neurons, 6-OHDA is oxidized like DA. The oxidized molecule generates free radicals 
inhibits mitochondrial complex I and produces superoxide and hydroxyl radicals (Bove, et 
al., 2005; Schober, 2004). It is not only toxic to the DAergic neurons but can also induce 
microglial activation (Bove, et al., 2005).  
Like MPTP, the pesticide rotenone is very lipophilic, crosses the BBB, and is distributed 
evenly throughout the brain (Bove, et al., 2005; Uversky, 2004). It can enter mitochondria, 
where it inhibits complex I of the electron transport chain with high affinity (Bove, et al., 
2005). Interestingly, the inhibition of microglial activation by an antibiotic,minocycline, can 
attenuate the neurotoxicity of rotenone (Casarejos et al., 2006). Gao et al. also showed that 
the neurotoxicity of rotenone is reduced in neuron-glia cocultures from NADPH oxidase-
null mice (Gao et al., 2003). The DA uptake of the neuron-enriched cultures was not affected 
by the addition of microglia from NADPH oxidase-null mice, the addition of microglia from 
wild-type (WT) mice significantly increased the sensitivity of DAergic neurons either from 
WT or knockout (KO) mice to rotenone neurotoxicity. These data indicate that microglial 
NADPH oxidase, but not neuronal NADPH oxidase, is responsible for the NADPH oxidase-
mediated neurotoxicity of rotenone (Gao, et al., 2003). Paraquat mainly crosses the BBB 
through the neutral amino acid transporter (McCormack & Di Monte, 2003; Shimizu et al., 
2003; Yang & Sun, 1998). Once in the brain, it is selectively taken up by the terminals of DA-
containing neurons in the substantia nigra by the DAT, and it inhibits mitochondrial 
complex I (Shimizu, et al., 2003). Maneb contains a major active fungicidal component, 
manganese ethylene-bis-dithiocarbamate (Mn–EBDC). In a rat model in which Mn–EBDC is 
directly delivered to the lateral ventricles, Mn–EBDC causes selective DAergic 
neurodegeneration (Zhang et al., 2003). Mn–EBDC preferentially inhibits mitochondrial 
complex III (Zhang, et al., 2003).  
4. Genetic animal models of PD 
Although the etiopathogenesis (including environmental factors) of PD is not fully 
understood, the extensive examination of human postmortem material, the genetic analysis 
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of patients, and the study of experimental animal models have shed significant light on the 
molecular mechanisms involved in its progression. However, since the number of patients 
with familial PD is extremely low compared to the number with sporadic PD, genetic 
studies in affected human families are very difficult. Therefore, the development of animal 
genetic models for PD is especially important, and such models provide an opportunity not 
only to investigate the genetic etiology of PD but also to identify new factors that could be 
invaluable in terms of diagnosis, drug design, and/or therapy (Gasser, 2009; Lees et al., 
2009). Even invertebrate animals, for example, Drosophila melanogaster, are useful models for 
surveys of human PD. While their numbers of neurons and glia are obviously much smaller 
than in rodents and primates, Drosophila have the same types of neuron-glia systems, and a 
great number of genes and molecular transduction pathways are conserved between 
Drosophila and humans.  
In recent years, several genetic animal models of PD have been reported, including models for 
autosomal-dominant (AD) inheritance patterns. The genes manipulated in these models 
include -synuclein, LRRK2, UCHL1, and high temperature requirement A2 (HTRA2/Omi) (Table 
2). There are also models of autosomal-recessive (AR) inherited PD, which involve KO or 
knockdown genes for parkin, DJ-1, and PINK1 (Table 3). In addition, we will review a PD 
mouse model deficient in nuclear receptor-related 1 (Nurr1), also named nuclear receptor subfamily 
4, group A, member 2 (NR4A2), which is a susceptibility gene for familial PD (Table 3). 
 
Gene Animal Manipulation
DA neuron 
loss 
LB-like 
inclusions1 
DA-responsive motor 
deficits2 
-synuclein 
(PARK1) 
Nematode Transgenic Yes§ No Yes 
Fly Transgenic Yes Yes Yes 
Mouse Transgenic No 
Yes§ 
(PrP promoter)
Yes§ 
(PDGF promoter) 
Rat Transgenic Yes No Yes 
Monkey Transgenic Yes No ND 
UCHL1 
(PARK5) 
Mouse Transgenic Yes No Yes 
LRRK2 
(PARK8) 
Nematode Transgenic Yes ND ND 
Fly Transgenic Yes No Yes 
Mouse Transgenic No No Yes 
Abbreviations: UCHL1, ubiqitin carboxy-terminal hydrolase L1; LRRK2, leucine-rich repeat kinase 2; DA, 
dopamine; LB, Lewy body; ND, not determined; PrP, prion; PDGFplatelet-derived growth factor 
1; LB-like inclusions by definition contain filamentous -synuclein 
2; ND could include some degree of behavioral impairment in spontaneous and locomotor activity and 
in response to sensory stimulation 
§; Controversial. The opposite result has also been shown. 
Table 2. Autosomal-dominant PD models 
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Gene Animal Manipulation
DA neuron 
loss 
LB-like 
inclusion1 
DA-responsive motor 
deficits2 
parkin 
(PARK2) 
Nematode Knockout No No No 
Fly 
Knockout Yes No Yes 
Transgenic Yes No Yes 
Mouse 
Knockout No No ND 
Transgenic Yes Yes ND 
PINK1 
(PARK6) 
Fly Knockout Yes No Yes 
Mouse Knockout No No ND 
DJ-1 
(PARK7) 
Fly Knockout Yes No Yes 
Mouse Knockout No No ND 
HtrA2/Omi 
(PARK13) 
Fly Knockout No No No 
Mouse Knockout No No ND 
Nurr1 
(NR4A2) 
Mouse Knockout Yes No ND 
Abbreviations: PINK1, phosphatase and tensin homolog deleted on chromosome ten (PTEN)-induced 
putative kinase 1; HtrA2, high temperature requirement A2; Nurr1, nuclear receptor-related 1; NR4A2, 
nuclear receptor subfamily 4, group A, member 2; DA, dopamine; LB, Lewy body; ND, not determined 
1; LB-like inclusions by definition contain filamentous -synuclein 
2; ND could include some degree of behavioral impairment in spontaneous and locomotor activity and 
in response to sensory stimulation 
Table 3. Autosomal-recessive PD models and other causative genes of PD 
4.1 -synuclein  
-synuclein was the first gene linked to an AD-type familial PD, called Park1. The identification 
of an -synuclein mutation in this family revolutionized PD research, since -synuclein is the 
main component of LBs, which are observed in the sporadic PD brain. This striking result 
strongly indicates that genetic and sporadic PD may share similar etiologies and that 
investigating -synuclein-mediated pathogenesis in familial PD could uncover important 
information about sporadic PD. Three missense mutations of -synuclein, encoding the 
substitutions A30P, A53T, and E46K, have been identified in familial PD (Gasser, 2009; Kruger 
et al., 1998; Lees, et al., 2009; Polymeropoulos et al., 1997). Furthermore, the duplication or 
triplication of -synuclein is sufficient to cause PD, suggesting that the level of -synuclein 
expression is a critical determinant of PD progression (Singleton, 2005; Singleton et al., 2003). 
Even though no direct relationship between sporadic PD and -synuclein expression has yet 
been shown, the existence of several polymorphisms in the promoter or 3’-UTR of the -
synuclein gene suggests that its expression level might be a risk factor (Holzmann et al., 2003; 
Pals et al., 2004; Winkler et al., 2007).  
Human -synuclein is an abundant 140-amino acid presynaptic phosphoprotein involved in 
vesicle handling and neurotransmitter release. Mutations in -synuclein that increase the 
propensity for misfolding are probably deleterious, because the misfolded forms are toxic, 
and they induce cell death in vitro (Cookson, 2005; Lee & Trojanowski, 2006). Among the 
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variety of abnormal forms that mutant -synuclein can adopt, protofibrils and fibrils seem 
to be the most toxic (Lee & Trojanowski, 2006). These demonstrations of -synuclein toxicity 
in vitro led to the creation and extensive analysis of many -synuclein-based animal models 
of PD.  
Although flies (Drosophila) and nematodes (C. elegans) do not have complex nervous systems 
compared to vertebrates and do not express endogenous -synuclein, they are useful for 
identifying genetic and pharmacological modifiers of -synuclein and its product. In 
Drosophila, the overexpression of WT and mutated (A30P, A53T) human -synuclein causes 
the age-dependent loss of dorsomedial DAergic neurons, an accumulation of LB-like 
filamentous inclusions with -synuclein immunoreactivity, and compromised locomotor 
activity (climbing ability) (Feany & Bender, 2000). In C. elegans, -synuclein overexpression 
leads to accelerated DAergic neuronal loss and motor impairment (Kuwahara et al., 2006; 
Lakso et al., 2003). However, the neurons of these nematodes do not contain notable 
synuclein-containing inclusions.  
Many different mouse lines that overexpress -synuclein under various promoters have 
been generated in the last ten years, and most have been described in recent reviews 
(Chesselet, 2008; Fernagut & Chesselet, 2004; Fleming & Chesselet, 2006). Mice expressing -
synuclein containing two mutations (A30P + A53T) under the TH promoter show 
progressive declines in locomotor activity and the loss of substantia nigra neurons and 
striatal DA content (Richfield et al., 2002; Thiruchelvam et al., 2004). Similarly, mice 
overexpressing WT human -synuclein under the neuron-specific platelet-derived growth 
factor  (PDGF) promoter show reduced TH immunoreactivity and DA content in the 
striatum and impaired motor performance (Masliah et al., 2000). Mice overexpressing WT 
human -synuclein under another neuron-specific promotor, Thy1, show strong 
widespread expression in cortical and subcortical neurons, including the substantia nigra 
pars compacta, but no glial, spinal, or neuromuscular pathology (Kahle et al., 2001; 
Rockenstein et al., 2002; Song et al., 2004). These mice have an increased sensitivity to 
mitochondrial damage from low doses of MPTP (Song, et al., 2004). Mice in which the 
mouse prion promoter (mPrP) is used to drive the expression of -synuclein A53T show -
synuclein aggregation, fibrils and truncation, -synuclein phosphorylation, ubiquitination, 
and progressive age-dependent neurodegeneration, just as in humans (Giasson et al., 2002; 
Lee et al., 2002).  
Several viral vectors, primarily lentiviruses and adenoassociated viruses (AAVs), have been 
used to drive exogenous -synuclein. Because viral vector delivery requires stereotactic 
injections within or near the site of the neuronal cell bodies in the substantia nigra pars 
compacta, rats are generally used for these studies although the model has been reproduced 
in other rodents (Kirik et al., 2002; Klein et al., 2002; Lauwers et al., 2003; Lo Bianco et al., 
2002). The overexpression of human WT or A53T mutant -synuclein by AAVs in the SNc 
neurons of rats causes the progressive age-dependent loss of DA neurons, motor 
impairment, and -synuclein-positive cytoplasmic inclusions (Kirik, et al., 2002). Kirik et al. 
also overexpressed WT or A53T mutant -synuclein in marmosets (Kirik et al., 2003), in 
which the -synuclein protein was expressed in 90%–95% of all substantia nigra DA 
neurons. The transduced neurons showed evidence of severe pathology, including -
synuclein-positive cytoplasmic inclusions, granular deposits, and loss of the TH-positivity.  
It is particularly notable that the phenotypic outcome of -synuclein overexpression in mice 
heavily depends on the promoter used to drive transgene expression. Unfortunately, most 
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of these models fail to accurately mimic PD in that there is no progressive loss of DA 
neurons. The loss of TH-positive cell bodies in the substantia nigra does not necessarily 
indicate cell death. Despite the lack of overt degenerative pathology in the DA-positive 
neurons, obvious locomoter abnormalities due to degeneration of the nigrostriatal system 
and a lack of DA responsiveness are observed in the various mouse -synuclein models. 
Thus, most of these lines are excellent models of -synuclein-induced neurodegenerative 
disorders, such as PD.  
Although mutated -synuclein causes human familial PD, -synuclein’s physiological roles 
in PD are not fully understood. In KO mice of -synuclein, neuronal development and the 
formation of presynaptic terminals are normal (Abeliovich et al., 2000). Moreover, double 
KO mice that lack - and -synuclein exhibit normal basic brain functions and survive to 
adulthood (Chandra et al., 2004). Thus, the loss of -synuclein function is unlikely to play a 
role in the pathogenesis of -synuclein-induced neurodegeneration. Meanwhile, -synuclein 
KO mice show reduced rearing activity in the open field, decreased DA content in the 
striatum, and a decrease in the reserve pool of vesicles in the hippocampus (Abeliovich, et 
al., 2000; Cabin et al., 2002). These results indicate that -synuclein may play a regulatory 
role in vivo, possibly in the fine tuning of synaptic plasticity and/or vesicle maintenance. 
Interestingly, several lines of -synuclein-null mice have a complete or partial resistance to 
the MPTP (Dauer et al., 2002; Schluter et al., 2003). Dauer et al. showed that this resistance is 
not due to abnormalities of the DA transporter, which appears to function normally in -
synuclein null mice (Dauer, et al., 2002). These reports indicate that -synuclein is not 
obligatorily coupled to MPTP sensitivity, but can influence MPTP toxicity on some genetic 
background. 
4.2 UCHL1  
A rare AD-inherited form of PD, PARK5, is caused by a missense mutation in the UCHL1 
gene. UCHL1 constitutes 1%-2% of the brain proteins and functions in the ubiquitin-
proteasome system. The ubiquitin hydrolase activity of UCHL1 is important for freeing 
reusable ubiquitin monomers. The missense mutation in PARK5 causes an Ile93Met 
substitution in the UCHL1 protein (UCHL1Ile93Met), and this mutant was initially shown 
to have decreased ubiquitin hydrolase activity (Leroy et al., 1998). Interestingly, UCHL1 is 
detected in LBs in sporadic PD cases (Lowe et al., 1990). These findings initiated a debate on 
whether the Ile93Met mutation causes a gain of function (toxicity) or loss of function 
(deficiency).  
The gracile axonal dystrophy (gad) mouse is an AR-mutant that shows sensory ataxia at an 
early stage, followed by motor ataxia. Saigoh et al. showed that these mice exhibit 
spontaneous intragenic deletion of the UCHL1 gene and do not express the UCHL1 protein 
(Saigoh et al., 1999). These mice do not show obvious pathological changes in the 
nigrostriatal DA pathway; in particular, there is no loss of DA cell bodies in the substantia 
nigra. Setsuie et al. generated transgenic mice that overexpressed UCHL1Ile93Met and 
reported a reduction in the DAergic neurons of the substantia nigra and of the DA content 
in the striatum (Setsuie et al., 2007). These mice show behavioral and pathological 
phenotypes of parkinsonism at 20 weeks of age. Moreover, recently, Yasuda et al. performed 
a viral vector-mediated -synuclein injection into the substantia nigra of the UCHL1Ile93Met 
transgenic mice (Yasuda et al., 2009). These mice show a significantly enhanced loss of DA-
positive cell bodies in the substantia nigra and of DA content in the striatum. The 
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neurotoxicity is enhanced by PARK5-associated UCHL1Ile93Met mutant, but not influenced 
by the loss of UCH-L1 WT protein in vivo, indicating that the UCHL1Ile93Met toxicity 
results from a gain of function. 
4.3 LRRK2  
The LRRK2 mutation is another type of ADPD, called PARK8. LRRK2 is a large protein 
containing a serine/threonine kinase and a GTPase domain that is localized to membranous 
structures (Biskup et al., 2006). The frequency of the common LRRK2 Gly2019Ser mutation 
was 1% in patients with sporadic PD and, interestingly, 4% of patients with hereditary PD 
(Healy et al., 2008). The risk of PD when the LRRK2 Gly2019Ser mutation was present was 
28% at age 59 years, 51% at 69 years, and 74% at 79 years. The motor symptoms and non-
motor symptoms of LRRK2-associated PD are more benign than those of idiopathic PD. In 
autopsied tissue, the LB pathology was present in a representative LRRK2 G2019S case, 
indicating that LRRK2 and -synuclein share some pathogenic mechanisms (Ross et al., 
2006). Yet, LRRK2 may play a role in neuronal outgrowth and guidance, and its precise 
physiological function remains to be clarified (MacLeod et al., 2006).  
dLRRK is a Drosophila orthologue of LRRK2, and it shows elevated expression in DA 
neurons of the head (Imai et al., 2008; Lee et al., 2007). Liu et al. overexpressed constructs 
with mutations similar to those found in patients (G2019S), in Drosophila (Liu et al., 2008). 
The neuronal expression of LRRK2 or LRRK2-G2019S produces an adult-onset selective loss 
of DAergic neurons, locomotor dysfunction, and early mortality. However, the phenotype 
caused by the G2019S-LRRK2 mutant is more severe than that cause by the expression of 
equivalent levels of WT LRRK2. Treatment with L-DOPA improves the mutant LRRK2-
induced locomotor impairment but does not prevent the loss of TH-positive neurons. Some 
fly models that overexpress other LRRK2 mutations, such as I1122V, Y1699C, and I2020T, 
show similar results, in terms of an age-dependent impairment of locomotor activity that 
improves with DA stimulation, and the loss of DA neurons (Liu, et al., 2008; Ng et al., 2009; 
Venderova et al., 2009). Moreover, in transgenic C. elegans, DA marker loss is greater in 
those expressing G2019S LRRK2 than WT LRRK2 (Saha et al., 2009).  
Transgenic mice made using bacterial artificial chromosome (BAC) technology and 
expressing WT LRRK2, or the R1441G or G2091S mutation exhibit mild axonal pathology in 
the nigrostriatal DA projection (Li et al., 2010; Li et al., 2009). However, the conditional 
overexpression of neither WT LRRK2 nor its G2019S mutation causes degeneration of the 
DA-containing neurons (Lin et al., 2009). Interestingly, although the LRRK2 conditional 
transgenic mice show minimal nigrostriatal pathologies, they exhibit a progressive age-
dependent motor impairment that is improved by DA stimulation. LRRK2 involvement in 
the pathogenesis of PD may be limited, and other genetic and/or environmental factors are 
probably required to trigger DA neuronal degeneration.  
LRRK2 KO mice are viable, have no major abnormalities, and live to adulthood, and there is 
no significant difference in the susceptibility of LRRK2-deficient and WT mice to MPTP 
(Andres-Mateos et al., 2009). In LRRK2-KO Drosophila models, differing results on the 
pathology of the DA neurons have been obtained (Imai, et al., 2008; Wang et al., 2008). Lee et 
al. showed that LRRK loss-of-function mutants exhibited severely impaired locomotive 
activity (Lee, et al., 2007). Moreover, DAergic neurons in LRRK mutants showed a severe 
reduction in tyrosine hydroxylase immunostaining and shrunken morphology. Conversely, 
Wang et al. demonstrated that mutants lacking dLRRK kinase activity are viable with 
www.intechopen.com
 
Mechanisms in Parkinson’s Disease – Models and Treatments 334 
normal development and life span as well as unchanged number and pattern of DAergic 
neurons (Wang, et al., 2008). Nematode deletion mutants indicate that LRRK2 is dispensable 
for the development and maintenance of DA neurons (Sakaguchi-Nakashima et al., 2007). 
4.4 Parkin  
Parkin covers approximately 1.3 Mb of genomic DNA and is the causative gene for 
representative AR juvenile PD (PARK2). Mutations in parkin are not only a cause of familial 
PD but are also seen in 20% of young-onset sporadic PD cases (Lucking et al., 2000). Parkin 
is an E3 ubiquitin ligase that functions in the ubiquitin-proteasome system. The loss of 
parkin function is believed to result in abnormal accumulations of parkin’s substrates. 
Springer et al. demonstrated that pdr-1 (the nematode parkin homolog) mutants are viable 
and display no obvious morphological defects or alterations in motility, egg-laying 
behavior, brood size, or life span under standard growth conditions (Springer et al., 2005). 
Moreover, the authors did not detect any effect of the mutations on the survival of the DA 
neurons in the worms. However, overexpression of the -synuclein A53T mutation in pdr-1 
mutants leads to developmental arrest and lethality, indicating this C. elegans model 
recapitulates parkin insolubility and aggregation similar to several AR juvenile PD-linked 
parkin mutations (Springer, et al., 2005).  
Drosophila parkin-null mutants exhibit a reduced lifespan, locomotor defects (flight and 
climbing abilities), and male sterility (Greene et al., 2003; Whitworth et al., 2005). The 
locomotor defects derive from the apoptotic cell death of muscle subsets whereas the male 
sterile phenotype derives from a spermatid individualization defect at a late stage of 
spermatogenesis. Mitochondrial pathology is the earliest manifestation of muscle 
degeneration and a prominent characteristic of individualizing spermatids in parkin 
mutants. These mutants also display a decrement in the TH level and degeneration of a 
subset of DA neurons in the brain (Whitworth, et al., 2005). Several parkin-null mice have 
been generated and display motor and cognitive deficits including reduced locomotor 
activity and decreased spontaneous alteration in the T-maze; however, they show no 
substantial DAergic behavioral abnormalities (Goldberg et al., 2003; Itier et al., 2003; Perez & 
Palmiter, 2005; Von Coelln et al., 2004). Pathologically, KO mice exhibit slightly abnormal 
DA nigrostriatal and locus coeruleus noradrenergic regions (Goldberg, et al., 2003; Von 
Coelln, et al., 2004).  
The overexpression of human mutant parkin in Drosophila causes an age-dependent, selective 
degeneration of DA neurons accompanied by progressive motor impairment (Sang et al., 
2007; Wang et al., 2007). Parkin-Q311X mice also exhibit multiple late-onset and progressive 
hypokinetic motor deficits (Lu et al., 2009). Stereological analyses revealed that the mutant 
mice develop age-dependent DA neuron degeneration in the substantia nigra and a 
significant reduction of the striatal DA level, accompanied by a significant loss of DA 
neuron terminals in the striatum. These results indicate that parkin mutants may play a 
pivotal role in the dominant-negative etiological mechanisms of PD. 
4.5 PINK1  
PINK1 is another causative gene for the AR inherited PD called PARK6. PARK6 is the 
second most frequent early-onset AR PD. PINK1 is located in mitochondria and is a putative 
mitochondrial kinase, because it contains a conserved serine/threonine kinase domain with 
an N-terminal mitochondrial-targeting motif (Silvestri et al., 2005). Thus, the PD-causative 
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mutations of PINK1 may cause loss of function. Park et al. and Clark et al. generated and 
characterized loss-of-function Drosophila PINK1 mutants (Clark et al., 2006; Park et al., 2006). 
These flies exhibit male sterility, apoptotic muscle degeneration, defects in mitochondrial 
morphology, and increased sensitivity to multiple stresses, including oxidative stress.  
Park et al. showed an age-dependent decrease in DA levels and a mild loss of DA neurons 
in these Drosophila mutants (Park, et al., 2006). Notably, the PINK1mutants share marked 
phenotypic similarities with parkin mutants. Parkin overexpression is able to rescue the 
mitochondrial defects found in PINK1, although the double mutants do not show an 
enhanced phenotype. PINK1 overexpression does not rescue parkin phenotypes. Together, 
the data indicate that parkin and PINK1 function, at least partly, in a common pathway, and 
PINK1 acts upstream of parkin. Whereas PINK1-deficient mice show age-dependent 
mitochondrial dysfunction, increased sensitivity to oxidative stress, decreased evoked DA 
release, and DA receptor agonist-responsive impairment of striatal plasticity, the number of 
DA neurons, the level of striatal DA, and the level of DA receptors are the same as in WT 
animals (Gautier et al., 2008; Gispert et al., 2009; Kitada et al., 2007). These phenotypes are 
similar to those of parkin-KO mice. 
4.6 DJ-1  
Deletion or point mutations in DJ-1 have been identified in early onset AR PD (PARK7). DJ-1 
plays a role as an antioxidant and chaperone, and it is expressed ubiquitously in the cytosol, 
mitochondrial matrix, and intermembranous space (Zhang et al., 2005). In vitro, 
downregulation or KO of the endogenous DJ-1 increases cells’ vulnerability to oxidative 
stress and proteasome inhibition, implicating it in the cellular response to oxidative stress 
(Martinat et al., 2004; Mitsumoto et al., 2001; Yokota et al., 2003). Drosophila possesses two 
different orthologs of the human DJ-1 gene, named DJ-1 and DJ-1. While loss-of-function 
DJ-1 mutants have normal numbers of DA neurons, classical genetic analyses and RNAi 
experiments have yielded contradictory results regarding the function of DJ-1 in DA 
neuron maintenance (Lavara-Culebras & Paricio, 2007; Menzies et al., 2005; Meulener et al., 
2005; Park et al., 2005; Yang et al., 2005). However, DA neuron loss cannot be detected inDJ-
1/DJ-1 double-deletion mutants, which are also viable, fertile, and have a normal life 
span. Some studies have reported a loss of DA neurons upon acute RNA silencing of DJ-1 
(Lavara-Culebras & Paricio, 2007; Yang, et al., 2005).  
Similar to -synuclein and parkin KO mice, DJ-1 KO mice do not show major DA-agonist-
responsive behavioral abnormalities or the loss of nigrostriatal DA neurons (Andres-Mateos 
et al., 2007; Goldberg et al., 2005; Kim et al., 2005). In particular, although the levels of 
striatal DA and DA receptors are unchanged, the evoked dopamine release from striatal 
slices is clearly reduced, most likely as a consequence of increased reuptake. DJ-1 mutant 
mice also show an increased sensitivity to MPTP (Kim, et al., 2005). This is rescued by 
restoring the DJ-1 expression in mutant mice, further indicating a role for DJ-1 in the 
oxidative stress response. 
4.7 HtrA2/Omi 
HtrA2/Omi has been identified as the causative gene for a rare inherited PD, PARK13. 
HtrA2/Omi has a PDZ (PDZ is based on three proteins that led to its discovery, 
postsynaptic density protein (PSD-95), Drosophila disc large tumor suppressor (DLG1), and 
zonula occludens-1 protein (ZO-1)) domain in addition to a serine protease domain and is 
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localized to the mitochondrial intermembrane space by its mitochondria-targeting sequence. 
Whitworth et al. have demonstrated a genetic interaction between HtrA2/Omi and PINK1, 
described below, by investigating the eye phenotype of double mutant flies (Whitworth et 
al., 2008). Their study revealed that HtrA2/Omi acts downstream of PINK1 and is 
independent of the parkin gene. Yet, Yun et al. indicated that HtrA2/Omi null fly mutants 
show neither mitochondrial morphological defects nor DAergic neuronal loss (Yun et al., 
2008). They also generated a Drosophila HtrA2/Omi mutant analogue to the human mutation 
G399S, which was identified in PARK13 patients. HtrA2/Omi G399S retains a significant, if 
not complete, function of HtrA2/Omi, compared with protease-compromised versions of 
the protein, indicating that HtrA2/Omi is unlikely to play a pivotal role in PD pathogenesis 
or as an etiological factor. The targeted deletion of HtrA2/Omi in mice increases their 
sensitivity to stress-induced cell death (Jones et al., 2003; Martins et al., 2004). Animals 
lacking HtrA2/Omi display a progressive movement disorder similar to progressive akinesia, 
a rigidity syndrome, showing lack of coordination, decreased mobility, bent posture, tremor, 
and a decreased number of TH-positive striatal neurons (Martins, et al., 2004). 
4.8 Nurr1 (NR4A2) 
Nurr1 is a member of the nuclear receptor superfamily and is involved in the differentiation 
and development of nigrostriatal DA neurons. Le et al. identified two mutations in Nurr1 
associated with PD (–291Tdel and –245T→G), which map to the first exon of NR4A2 and 
affected one allele in 10 of 107 individuals with familial PD (Le et al., 2003). Mutations in 
Nurr1 alter the transcription of TH and the DA transporter, suggesting that alterations in 
Nurr1 may cause chronic DA alterations that could increase susceptibility to PD (Sacchetti et 
al., 2001). Nurr1 is essential for the development of the ventral mesencephalic DA neurons, 
because homozygous Nurr1-KO mice do not develop DA neurons in the substantia nigra 
and die soon after birth (Zetterstrom et al., 1997). Heterozygous Nurr1-KO mice exhibit a 
significant decrease in rotarod performance and locomotor activities (Jiang et al., 2005). 
These phenotypes are associated with decreased DA levels in the striatum, decreased 
numbers of DAergic neurons, and a reduced expression of Nurr1 and DAT in the substantia 
nigra. Moreover, Le et al. reported that heterozygous Nurr1-KO mice show a significant 
decrease in the total number of TH-positive neurons in the substantia nigra and reduced DA 
in the striatum after MPTP administration (Le et al., 1999). Thus, these mice show a 
progressive DA phenotype that bears some resemblance to that found in -synuclein-
overexpressing and mutant mice. Therefore, Nurr1-knockdown mice may provide a good 
model for investigating the later stages of PD characterized by severe DA neuron loss. 
5. Genetic risk factors of PD 
The identification and characterization of susceptibility genes for common human disease, 
including PD, is a difficult challenge. The usual approach of focusing a study on just one or 
a few candidate genes limits our ability to identify novel genetic effects associated with 
disease. In addition, many susceptibility genes may exhibit effects that are partially or solely 
dependent on interactions with other genes and/or the environment. Recently, Genome-
wide association studies (GWAS) have been proposed as a solution to these problems. 
GWAS analyses must embrace abundant clinical and environmental data available to 
complement the rich genotypic data with the ultimate goal of revealing the genetic and 
environmental factors important for disease risk.  
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In 2009, two reports of GWAS demonstrated that several genes and loci could be genetic risk 
factors for PD in the different population (Satake et al., 2009; Simon-Sanchez et al., 2009). 
These studies indicated that -synuclein, LRRK2, and locus on 1q32 (designated as PARK16) 
showed strong association to PD. Interestingly, BST1 on 4q15 is only identified a new risk 
locus in the Japanese study (Satake, et al., 2009) and microtubule-associated protein tau (MAPT) 
is only found association in the European study (Simon-Sanchez, et al., 2009), indicating that 
population-specific genetic heterogeneity involves in the pathogenesis of PD.  
MAPT is primarily expressed in neurons and plays a key role in the organization and 
integrity of the cytoskeleton and filamentous neuronal tau inclusions define a set of 
neurodegenerative diseases referred to as the “tauopathies,” which include Alzheimer’s 
disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). While tau 
pathology is sometimes found in PD, it is not pathognomic. Thus, the relationship between 
the MAPT and the pathophysiology of PD still remains to be elucidated, however, brain 
pathology in Alzheimer’s disease cases with amyloid precursor protein mutation exhibits 
not only -amyloid deposition, tangle, but also sometimes LB pathology (Hardy, 1994). This 
finding indicates that there are genetic pathologic connections between -synuclein and tau.  
Other GWAS demonstrated that the strongest evidence of association was obtained on 
chromosome 4p16 in the gene cyclin G associated kinase (GAK), designated as PARK17 
(Hamza et al., 2010; Pankratz et al., 2009). This gene might be a promising candidate since 
the expression of cell cycle regulators altered in the substantia nigra pars compacta with PD 
(Grunblatt et al., 2004). 
More recent GWAS showed a new genetic association with PD in the human leukocyte antigen 
(HLA)-DRA region (6p21), designated as PARK18 (Hamza, et al., 2010). Interestingly, this 
result suggests an involvement of immune system in the pathogenesis of PD. Furthermore, 
genetic variability of HLA region potentially has impact on damage repair and cleaning up 
risk for disease. The adaptive or innate immune systems had previously been implicated in 
disease pathology in the late-onset neurodegenerative diseases such as PD and Alzheimer’s 
disease (McGeer et al., 2005).  
Gaucher disease (GD) is an autosomal recessive glycolipid storage disorder with 
multisystemic manifestations caused by loss of function mutations in the glucocerebrosidase 
(GBA) gene, which encodes the enzyme glucocerebrosidase. A small subset of patients with 
GD develops parkinsonism with brain stem or diffuses LB-related pathology (Wong et al., 
2004). An increased incidence of parkinsonism has also been reported in relatives of patients 
with PD (Halperin et al., 2006). In 2009, multicenter analysis demonstrated that there is a 
strong association between GBA mutations (L444P and N370S) and PD (Sidransky et al., 
2009). While both gain-of- and loss-of- function hypotheses have been proposed, he 
mechanism by which GBA mutations increase risk for PD is not fully known (Velayati et al., 
2010).  
Additional susceptibility loci will likely be uncovered in the near future, as the wealth of 
recent data from GWASs is further analyzed. Such efforts will include meta-analysis, 
consideration of gene-gene and gene -environment interaction, and analysis of copy number 
variation. Although important progress has been made, the mechanisms by which variation 
in PD-linked genes leads to neurodegeneration remains poorly understood. However, data 
accumulated thus far has implicated mitochondrial dysfunction, oxidative damage, aberrant 
protein aggregation, deficits in ubiquitin-mediated protein degradation, and malfunction of 
immune system as playing key roles in the etiopathogenesis of PD. Actually, animal models 
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of these risk factor gene mutations have been described very few, but once they are available 
(if pathological features including LB and clinical manifestation are replicated by candidate 
genes manipulation), they will undoubtedly shed new light on the mechanisms of PD.  
6. Concluding remarks 
The symptoms of PD become apparent after more than 80% of the DA neurons have died. 
The rate of substantia nigral cell loss is assumed to be about 2,500 per year in normal people. 
The loss of DA function can be accelerated by exposure to neurotoxins and by molecular 
(genetic) abnormalities, leading to a fast and significant decrease in the number of DA 
neurons. Consequently, these pharmacological and/or genetic insults can cause early onset 
of PD. This scenario indicates that critical pathological changes could be initiated one or two 
decades prior to the onset of PD. As described above, whether the causative factor is a toxic 
compound or a mutated gene, we have no perfect animal models of PD. So far, the 
neurotoxin-induced vertebrate models of PD are suitable for investigating disease-
modifying therapies, since they have already proved predictive. Several genetic animal 
models of PD are useful for understanding the early processes of degeneration in the 
nigrostriatal DA system. In particular, transgenic -synuclein animals are valuable for 
researching general toxicity effects and the mechanisms of -synuclein pathology, as well as 
for confirming potential therapeutic strategies. 
Neurotoxic and genetic models of PD have opened new perspectives for modeling and 
understanding the progression of PD but the advantages and disadvantages of each 
approach must be carefully considered. As described above, some models of PD induced by 
toxins and mutations exhibit insoluble -synuclein inclusions in the pathological feature, 
however, they fail to exhibit true LBs. It is important to distinguish models that reproduce 
the progressive degeneration of nigrostriatal DA neurons from those that model disease 
progression in the whole organism. Genetic modeling of nigrostriatal degeneration 
complements toxin-induced neuronal loss by reproducing insults that are mechanistically 
linked to PD in humans. These models can provide useful information on stages of 
neurodegeneration, in particular on the interplay between protective and detrimental 
mechanisms, which are likely to contribute to the late onset of the disease and the effect of 
aging, a main risk factor for PD.  
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